GO
Loading...

Merck & Co Inc

More

  • Merck Settles Vioxx Claims for $4.85 Billion Friday, 9 Nov 2007 | 3:53 PM ET
    Merck Vioxx

    Merck has agreed to pay $4.85 billion to settle claims that its painkiller Vioxx caused heart attacks and strokes in thousands of users, the drugmaker said Friday.

  • The surprising Vioxx settlement brought me back to the office today in the middle of my vacation--I could've literally phoned it in as I did on "Squawk Box" this morning, but as long as I was in town, I'm too hard core to stay at home working around the house when a big story like this one breaks on my beat.

  • Wider Use of Big-Selling Drug Crestor Approved Friday, 9 Nov 2007 | 5:28 AM ET

    AstraZeneca has won U.S. approval to market its cholesterol-lowering drug Crestor to treat the clogging of arteries, which may boost sales of the blockbuster drug in an increasingly competitive market.

  • Novartis Diabetes Drug Faces Further Delays Tuesday, 6 Nov 2007 | 3:44 AM ET
    Novartis

    Novartis has found safety problems in higher doses of its key Galvus diabetes drug and will revise prescribing recommendations before launching in Europe.

  • Zocor

    This morning we got more evidence about the havoc generic Zocor is wreaking on all of the companies that make brand-name statins--the pills to fight cholesterol. AstraZeneca is the latest casualty. On a down day in the markets AZN is one of the biggest losers in the sector.

  • Lipitor

    Pfizer has been using Dr. Robert Jarvik, the inventor of the Jarvik Artificial Heart, for quite some time now as its Lipitor "celebrity" pitchman. But recently I've noticed something remarkable creeping into his copy--the script he reads for TV and radio spots and the text that appears in the print ads.

  • Merck, Sanofi, Glaxo Get "Shot In The Arm" From U.K. Friday, 26 Oct 2007 | 12:52 PM ET

    British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.

  • Stocks Close Higher After Wild Trading Session Monday, 22 Oct 2007 | 4:29 PM ET

    Stocks rallied late in the session to end a seesaw trading session higher as bargain hunters stepped in despite economic concerns and worries about global credit markets. "It seems like a little bit of a bounce back from Friday's Armageddon," said Mike Burnick, director of research at the Sovereign Society.

  • Pharma Stock Picks From a Five-Star Fund Manager Monday, 22 Oct 2007 | 1:05 PM ET

    To a five-star fund manager, it's not how big the stars are, but how brightly they're shining.  In the pharmaceutical field, Kris Jenner of T. Rowe Price finds brightness at both ends of the size spectrum.

  • Schering Plough: Why It's Down And Merck's Up Monday, 22 Oct 2007 | 12:24 PM ET

    Here are my thoughts so far today: 1) As expected, sloppy trading--weak open, modest rally, sell into rally. The crowd yelling "oversold" cannot drown out the great majority, who feel it is not really worth it to be a hero until things settle down.

  • Schering Results Miss Targets; Shares Plunge Monday, 22 Oct 2007 | 10:27 AM ET

    Schering-Plough on Monday reported third-quarter profit and sales that fell short of Wall Street's target, sending shares down more than 10 percent amid concerns about its flagship cholesterol drugs

  • Merck's Profit Jumps 62%; Drug Maker Raises Outlook Monday, 22 Oct 2007 | 9:40 AM ET

    Merck reported a better-than-expected profit, helped by sales of its vaccines and cholesterol drugs, and raised its 2007 profit forecast in view of strong current trends.

  • Chance to Recoup Stock Losses to Hinge on Earnings Sunday, 21 Oct 2007 | 11:28 AM ET

    U.S. stock investors looking to recoup from the worst week in almost three months will have to keep one eye out for signs of weakness in earnings due this week and the other on the threat surging oil prices.

  • Market Insider: The Week Ahead Friday, 19 Oct 2007 | 9:23 PM ET

    Fear returned to Wall Street this past week, and the Fed's meeting Oct. 31 is now being looked at as a necessary balm for the markets.  Rightly or wrongly, that's how traders are see it, and they now expect the Fed to cut its target Fed funds rate and probably discount rate by a quarter point at that meeting.

  • Gilead HIV Drugs Drive Profit After Year-Ago Loss Thursday, 18 Oct 2007 | 7:17 PM ET

    Gilead Sciences posted a third-quarter profit that topped Wall Street targets on Thursday, on sales of drugs that fight the virus that causes AIDS, compared with a year-ago net loss due to acquisition- related costs.

  • Pfizer Earnings Fall 77%, Hurt by Insulin Drug Exit Thursday, 18 Oct 2007 | 9:42 AM ET
    Pfizer

    Pfizer said on Thursday that third-quarter earnings fell sharply, hurt by a $2.8 billion charge to end its investment in its poorly selling Exubera inhaled insulin drug. But earnings excluding one-time items beat analysts' expectations.

  • Merck Wins FDA Approval for AIDS Drug Friday, 12 Oct 2007 | 5:09 PM ET

    U.S. regulators approved a new AIDS treatment made by Merck, the first in a new class of drugs aimed at preventing replication of the virus, Merck said on Friday.

  • Comings & Goings at Pfizer & Glaxo Monday, 8 Oct 2007 | 1:30 PM ET

    This morning, the world's second biggest drug company, GlaxoSmithKline, announced that Andrew Witty will replace JP Garnier as CEO at the end of next May. It's been known for a while that Garnier would be retiring next year, and the question was who would be tapped to succeed him.

  • Stocks rallied on Friday, sending the S&P 500 index to a new closing record, as a solid employment report rekindled optimism about the outlook for economic growth and corporate profits. The Dow Jones Industrial Average, meanwhile, traded above its record close for much of the session but gave back some of those gains.

  • Pfizer's Inside R&D Move: Are Investors Buying It? Thursday, 4 Oct 2007 | 1:25 PM ET

    Close on the heels of announcing the hiring of a Chief Talent Officer, Pfizer this morning named a new head of Global Research and Development to replace John LaMattina who had earlier said he'd be leaving the drug company. It was on LaMattina's watch that Pfizer's next potential breakout blockbuster drug, torcetrapib for cholesterol, failed in a late-stage clinical trial.